BG Medicine, Inc. (BGMD)
-NasdaqGM 1.80 
0.03(1.69%) 2:25PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.77 |
|---|
| Open: | 1.75 |
|---|
| Bid: | 1.80 x 3400 |
|---|
| Ask: | 1.81 x 2000 |
|---|
| 1y Target Est: | 4.33 |
|---|
| Beta: | 3.54 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.72 - 1.82 |
|---|
| 52wk Range: | 1.00 - 7.10 |
|---|
| Volume: | 63,751 |
|---|
| Avg Vol (3m): | 246,100 |
|---|
| Market Cap: | 49.64M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.00 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Life Science Industry Veteran Stephane Bancel Joins Flagship VenturesPR Newswire(Wed, May 22)
- BG MEDICINE, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;EDGAR Online(Fri, May 17)
- Emerging Biomarker Companies Redux: Positioned For Growthat Seeking Alpha(Wed, May 15)
- BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire(Fri, May 10)
- BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online(Fri, May 10)
- BG MEDICINE, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- BG Medicine's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- BG Medicine appoints Dr. Paul Sohmer as CEOtheflyonthewall.com(Thu, May 9)
- BG Medicine Appoints Dr. Paul Sohmer as Chief Executive OfficerGlobeNewswire(Thu, May 9)
- BG Medicine Reports 2013 First Quarter Financial ResultsGlobeNewswire(Thu, May 9)
- Q1 2013 BG Medicine Inc Earnings Release - Before Market OpenCCBN(Thu, May 9)
- BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and FinancialEDGAR Online(Thu, May 9)
- Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital ReadmissionsGlobeNewswire(Wed, May 8)
- BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013GlobeNewswire(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 15.15 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.77 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States.
View More